Therapeutic antibody formulation

A bufferless aqueous pharmaceutical formulation comprising:

• (i) an anti-IL-17A antibody at a concentration of 80 mg/mL+/−10%;
• (ii) sucrose in a concentration of 234 mM+/−10%;
• and
• (iv) a surfactant in a concentration of between 0.005% w/v+/−10% to 0.05% w/v+/−10%,
• wherein, the pharmaceutical formulation is an aqueous solution at a pH between 5.2 to 6.5 and the anti-IL17A antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, wherein:
• LCDR1 comprises the amino acid sequence of SEQ ID NO. 1,
• LCDR2 comprises the amino acid sequence of SEQ ID NO. 2,
• LCDR3 comprises the amino acid sequence of SEQ ID NO. 3,
• HCDR1 comprises the amino acid sequence of SEQ ID NO. 4,
• HCDR2 comprises the amino acid sequence of SEQ ID NO. 5, and
• HCDR3 comprises the amino acid sequence of SEQ ID NO. 6.